推广 热搜: 福的  Himedia  Mibio/酶联  实验室  试剂盒  冷冻离心机  lonza  设备  仪器  试剂 

重组人源anti-COVID-19/SARS-CoV-2 RBD 单克隆抗体

点击图片查看原图
 
单价: 3500.00
品牌: 卡梅德生物
销量: 累计出售 0
评价: 已有 0 条评价
人气: 已有 72 人关注
更新: 2021-02-08
数量: 减少 增加件 库存1000件
立即购买   加入购物车
 
公司基本资料信息
 
 
产品编号 MAV101
产品名称 Recombinant Human anti-COVID-19/SARS-CoV-2 RBD Monoclonal Antibody
抗体亚型 IgG1
克隆号 1G6
产品别名 SARS-CoV-2 RBD antibody, 2019-nCoV, Coronavirus
规格 100ul, 500ul
规格与价格 100ul/¥3,500; 500ul/¥9,000; 1000ul/¥16,000
物种 COVID-19
宿主 Human
免疫原 Native virus
产品应用 ELISA, Colloidal Gold, POCT, Neutralizaiton , Standard Positive Control
生物活性 IC50 = 2.8 ng/mL using SARS-CoV-2 Inhibitor screening Kit
缓冲体系 0.01M PBS, pH 7.4
产品背景 A novel severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV-2) recently emerged and is rapidly spreading in humans, causing COVID-19. A key to tackling this pandemic is to understand the receptor recognition mechanism of the virus, which regulates its infectivity, pathogenesis and host range. SARS-CoV-2 and SARS-CoV recognize the same receptor—angiotensin-converting enzyme 2 (ACE2)—in humans. Researchers determined the crystal structure of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 (engineered to facilitate crystallization) in complex with ACE2. In comparison with the SARS-CoV RBD, an ACE2-binding ridge in SARS-CoV-2 RBD has a more compact conformation; moreover, several residue changes in the SARS-CoV-2 RBD stabilize two virus-binding hotspots at the RBD–ACE2 interface. These structural features of SARS-CoV-2 RBD increase its ACE2-binding affinity. Additionally, we show that RaTG13, a bat coronavirus that is closely related to SARS-CoV-2, also uses human ACE2 as its receptor.
保存条件 This product can be stored at 2℃-8℃ for one month. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Avoid repeated freeze-thaw cycles.
备注 This product is used for research use only. Not for human or diagnostic use.
网站首页  |  关于我们  |  联系方式  |  使用协议  |  版权隐私  |  网站地图  |  排名推广  |  积分换礼  |  网站留言  |  RSS订阅  |  违规举报